Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

Summary

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.

Eligibility

Inclusion Criteria:

Project 1: HealthKit

* Individuals who meet at least one of the following criteria:

  * Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
  * Historical diagnosis of primary invasive solid tumor
  * Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
  * Enrolled onto an investigational trial in the EDD Service
  * Seen in the MSK UCC from 2021 and onwards
  * Completion of Survivorship Patient Self-Assessment
  * Adult without a history of cancer \<50 years of age
  * Adult without a history of cancer ≥ 50 years of age
* ≥18 years old
* Own an Apple iPhone with valid iOS operating software
* Have a registered MSK MyChart account and be willing to download the MSK Remote Monitoring (RM) application onto their personal iPhone
* Self-reported "very well" comprehension of written and verbal English language
* Willing and able to provide informed consent and HIPAA authorization for the release of personal health information

Project 2: DigIT-Ex

Individuals who meet one of the following criteria:

* Patients at MSK who are:
* Scheduled to undergo any type of BMT (Cohort 1)
* Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)
* Scheduled to undergo any surgery for prostate cancer (Cohort 3)
* Scheduled to undergo any lung cancer surgery (Cohort 4)
* Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)
* Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):
* High risk/very high localized, locally advanced,
* Biochemically recurrent prostate cancer
* Treatment naïve, low-volume metastatic prostate cancer
* Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)
* Individuals without cancer \<50 years of age (Cohort 8)
* Individuals without cancer ≥50 years of age (Cohort 9)

  * 18 to 90 years old at the time of consent
  * Willing and able to download the Withings Health Mate app onto their personal mobile device
  * Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent
  * Willing to provide informed consent

Exclusion Criteria:

Project 1: HealthKit

* Unable or unwilling to successfully export and /or share physiological data

Project 2: DigIT-Ex

* Unable or unwilling to appropriately use digital platforms or devices

Conditions2

Locations1 site

Browse More Trials